• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Neurocrine Bioscienc (NQ: NBIX )

    137.49 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 12
    Open 137.49
    Bid (Size) 130.50 (4)
    Ask (Size) 142.00 (1)
    Prev. Close 137.49
    Today's Range 137.49 - 137.49
    52wk Range 93.28 - 148.37
    Shares Outstanding 100,600,000
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Despite its impressive fundamentals, NASDAQ:NBIX remains undervalued.
    NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), an undervalued stock with good fundamentals. 
    Via Chartmill
    7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
    With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. 
    Via InvestorPlace

    Performance

    YTD
    +4.37%
    +4.37%
    1 Month
    -1.74%
    -1.74%
    3 Month
    -0.18%
    -0.18%
    6 Month
    +4.37%
    +4.37%
    1 Year
    +45.52%
    +45.52%

    More News

    Read More
    Is NASDAQ:NBIX on the Verge of a Major Breakout as a Strong Growth Stock?
    Via Chartmill
    Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
    Via Investor's Business Daily
    Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation.
    Via Chartmill
    Key Takeaways From Neurocrine Biosciences Analyst Ratings
    Via Benzinga
    Exploring NASDAQ:NBIX's quality characteristics.
    Via Chartmill
    Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.
    Via Chartmill
    In the world of growth stocks, NASDAQ:NBIX shines as a value proposition.
    Via Chartmill
    Nvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam
    Via Investor's Business Daily
    A Week Of Fast-Moving Stocks Ahead: Disney, Toyota, Ferrari, Constellation
    Via Investor's Business Daily
    Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
    Via Investor's Business Daily
    Topics Economy
    Exposures Interest Rates
    Why Quality Investors May Find NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Attractive.
    Via Chartmill
    NASDAQ:NBIX, a strong growth stock, setting up for a breakout.
    Via Chartmill
    Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences
    Via Benzinga
    Despite its growth, NASDAQ:NBIX remains within the realm of affordability.
    Via Chartmill
    PTC Therapeutics Stock Sees IBD RS Rating Climb To 72
    Via Investor's Business Daily
    NBIX Stock Earnings: Neurocrine Biosciences Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    No. 1 Biotech Stock Neurocrine Pops After Its Biggest Moneymaker Snatches Another Win
    Via Investor's Business Daily
    Sarepta Therapeutics Stock Shows Improved Technical Strength
    Via Investor's Business Daily
    Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
    Via Investor's Business Daily
    3 Red-Hot Biotech Rockets Blasting Off in 2024
    Via InvestorPlace
    Topics Economy
    Exposures Economy
    Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
    Via Benzinga
    No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win
    Via Investor's Business Daily
    Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
    From Sentia Medical Sciences, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.